References
1. Global Hepatitis Report 2017. Geneva: World Health Organization, 2017. URL: http://www.who.int/hepatitis/publications/global-hepatitis-report2017/en/
2. Global Health Sector Strategy on Viral Hepatitis, 2016-2021. Geneva: World Health Organization, 2016. URL: http://www.who.int/hepa-titis/strategy2016-2021/ghss-hep/ru/
3. Razavi H., Elkhoury A.C., Elbasha E., Estes C., Pasini K., Poynard T., et al. Chronic hepatitis C virus (HCV) disease burden and cost in the United States. Hepatology. 2013; 57: 2164-2170.
4. Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol. Hepatol. 2017; 2 (3): 161-76.
5. Yushchuk N.D., Znoyko O.O., Yakushechkina N.A., Zyryanov S.K., Shut’ko S.A., Belyy P.A., et al. The burden of viral hepatitides in the Russian Federation and ways of its reduction for the long term (in case of hepatitis C). Terapevticheskiy arkhiv [Therapeutic Archive]. 2013; (12): 79-85. (in Russian)
6. Chen S.L., Morgan T.R. The natural history of hepatitis C virus (HCV) infection. Int J Med Sci. 2006; 3: 47-52. DOI: https://doi.org/10.7150/ijms.3.47
7. Poynard T., Ratziu V., Charlotte F., Goodman Z., McHutchison J., Albrecht J. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J Hepatol. 2001; 34 (5): 730-9. DOI: https://doi. org/10.1016/s0168-8278(00)00097-0
8. Seeff L.B. Natural history of chronic hepatitis C. Hepatology. 2002; 36 (5B): s35-46. DOI: https://doi.org/10.1053/jhep.2002.36806
9. Grassly N.C., Fraser C. Mathematical models of infectious disease transmission. Nat Rev Microbiol. 2008; 6 (6): 477-87. DOI: https://doi.org/10.1038/nrmicro1845
10. Porgo T.V., Norris S.L., Salanti G., et al. The use of mathematical modeling studies for evidence synthesis and guideline development: a glossary. Res Synth Methods. 2019; 10: 125-33.
11. Zaman G., Jung I.H., Torres D.F.M., Zeb A. Mathematical modeling and control of infectious diseases. Comput Math Methods Med. 2017; 2017: 7149154.
12. Fojo A.T., Kendall E.A., Kasaie P, Shrestha S., Louis T.A., Dowdy D.W. Mathematical modeling of «chronic» infectious diseases: unpacking the black box. Open Forum Infect Dis. 2017; 4 (4): ofx172. DOI: https://doi.org/10.1093/ofid/ofx172
13. Yushchuk N.D., Ivakhnenko O.I., Znoyko O.O., Klimova E.A., Du-dina K.R., Belyy P.A., et al. Modeling the epidemiological situation with viral hepatitis C In the Russian Federation: opportunities and challenges. Infekt-sionnye bolezni [Infectious Diseases]. 2019; 17 (1): 105-14. DOI: https://doi.org/10.20953/1729-9225-2019-1-105-11 (in Russian)
14. Thein H.-H., Yi Q., Dore G.J., Krahn M.D. Estimation of stage-specific fibrosis progression rates in chronic hepatitis c virus infection: a metaanalysis and meta-regression. Hepatology. 2008; 48: 418-31.
15. Fattovich G., Giustina G., Degos F., Tremolada F., Diodati G., Almasio P, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology. 1997; 112: 463-72.
16. Yoshida H., Shiratori Y., Moriyama M., Arakawa Y., Ide T., Sata M. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. Ann Intern Med. 1999; 131: 174-81.
17. Soboleva N.V., Karlsen A.A., Kozhanova T.V., Kichatova V.S., et al. The prevalence of the hepatitis C virus among the conditionally healthy population of the Russian Federation. Zhurnal infektologii [Journal of Infec-tology]. 2017; 9 (2): 56-64. (in Russian)
18. Bogomolov P.O., Bueverov A.O., Matsievich M.V., Petrachen-kova M.Yu., et al. Epidemiology of hepatitis C in the Moscow Region: data from the Moscow Regional Registry and screening for HCV antibodies. Al’manakh klinicheskoy meditsiny [Almanac of Clinical Medicine]. 2016; 44 (6): 689-96. (in Russian)
19. Kyuregyan К.К., Soboleva N.V., Karlsen А.А., Kichatova V.S., et al. Dynamic changes in the prevalence of hepatitis C virus in the general population in the Republic of Sakha (Yakutia) over the last 10 years. Infektsionnye bolezni: novosti, mneniya, obuchenie [Infectious Diseases: News, Opinions, Training]. 2019; 8 (2): 16-26. DOI: https://doi.org/10.24411/2305-3496-2019-12002 (in Russian)
20. Kravchenko I.E., Ginyatullin R.R., Amon E.P., Malinnikova E.Yu. State of medical care for patients with chronic hepatitis C in Russian Federation. Infektsionnye bolezni: novosti, mneniya, obuchenie [Infectious Diseases: News, Opinions, Training]. 2019; 8 (4): 48-57. DOI: https://doi.org/10.24411/2305-3496-2019-14007 (in Russian)
21. Materials of the video conference call of the Ministry of Health of the Russian Federation "Actual issues of providing medical care to patients with viral hepatitis", December 22, 2016: Report of V.P. Chulanov. Epidemiological surveillance of viral hepatitis. Monitoring system for viral hepatitis in the Russian Federation. URL: https://www.rosminzdrav.ru/news/2016/12/26/3362-v-minzdrave-rossii-proshlo-videoselek-tornoe-soveschanie-aktualnye-voprosy-okazaniya-meditsinskoy-pomoschi-bolnym-virusnymi-gepatitami (in Russian)
22. Yakovlev A.A. Treating viral hepatitis C in 2019 Expanding elimination options. In: Russian scientific-practical conference "Controlled and other socially significant infections: diagnosis, treatment and prevention". Saint Petersburg, 2019. URL: http://congress-ph.ru/common/htdocs/up-load/fm/detinf/19/03-2019/prez/039.pdf (in Russian)
23. Information about the number of diseases. Rosstat. Showcase of statistical data. URL: https://showdata.gks.ru/finder/reports/ (in Russian)
24. Nurmukhametova E.A., Blokhina N.P., Smetanina S.V. Organization of medical care and drug provision for patients with chronic hepatitis C in Moscow. Dokazatel’naya gastroenterologiya [Evidence-Based Gastroenterology]. 2019; 8 (1): 84-92. DOI: https://doi.org/10.17116/dok-gastro201980118 (in Russian)
25. Perasperaad DAA. Results of monitoring the procurement of drugs for the treatment of hepatitis C in Russia in 2019-2020. In: Treatment Preparedness Coalition. Saint Petersburg, July 2020. (in Russian)
26. Sepanlou S.G., Safiri S., Bisignano C., Ikuta K.S., Merat S., Sa-berifiroozi M., et al. The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2020; 5 (3): 245-66. DOI: https://doi.org/10.1016/s2468-1253(19)30349-8
27. Yushchuk N.D., Zayrat’yants O.V., Znoyko O.O., et al. The burden of death from viral hepatitis B and C: assessment methodology and indicators in Moscow in 2015-2017. Infektsionnye bolezni: novosti, mneniya, obuchenie [Infectious Diseases: News, Opinions, Training]. 2018; 7 (4): 8-14. DOI: https://doi.org/10.24411/2305-3496-2018-14001 (in Russian)
28. Pimenov N.N., Komarova S.V., Karandashova I.V., Tsapkova N.N., et al. Hepatitis С and its outcomes in Russia: analysis of incidence, prevalence and mortality rates before the start of the programme of infection elimination. Infektsionnye bolezni [Infectious Diseases]. 2018; 16 (3): 37-45. DOI: https://doi.org/10.20953/1729-9225-2018-3-37-45 (in Russian)